Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics

Alaadin Alayoubi, Baher Daihom, Hitesh Adhikari, Sanjay Mishra, Richard Helms, Hassan Almoazen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Abstract: Purpose: The purpose of this study is to develop an oral suspension of clindamycin resin complex for the potential use in pediatrics. Methods: Several types of Ion exchange resins were screened for their binding efficiency with clindamycin. In order to develop a suspension formulation, several thickening agents, surfactants, sweeting, and flavoring agents were evaluated for their influence on the release of clindamycin from resinate. Rheological studies were also conducted to select the optimum amounts of the suspending agents. The release profiles of clindamycin in SGF and SIF were also evaluated from freshly prepared suspension and from suspension formulation after storage for 1 month at 25 °C and 40 °C. Clindamycin bitterness threshold was determined based on volunteers’ evaluation, and taste evaluation was conducted in 12 adult volunteers who evaluated the taste of the optimized suspension against clindamycin solution. Results: Among all resins tested, Amberlite IRP 69 showed the highest binding efficiency to clindamycin. Several excipients were selected into the suspension formulation based on no or minimum influence on the release of clindamycin from the resinate complex. Moreover, xanthan gum was selected as the optimal suspending agent for the suspension. Clindamycin release profiles in SGF or SIF showed 90% release within 30 min from freshly prepared sample. Clindamycin exhibited good stability profiles at 25 °C and 40 °C over 1 month storage. The mean bitterness threshold of clindamycin was 12.5 μg/ml, and taste evaluation study in adults showed sustainable taste improvement for suspension over clindamycin solution. Conclusion: Clindamycin/resin complexation has shown to be an efficient method to mask the taste of clindamycin and was developed into a suspension formulation that can be used in pediatrics.

Original languageEnglish (US)
Pages (from-to)1579-1589
Number of pages11
JournalDrug Development and Industrial Pharmacy
Volume42
Issue number10
DOIs
StatePublished - Oct 2 2016

Fingerprint

Ion Exchange Resins
Pediatrics
Clindamycin
Suspensions
Excipients
Resins
amberlite IRP 69
Volunteers
Flavoring Agents
Masks
Complexation
Surface-Active Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cite this

Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics. / Alayoubi, Alaadin; Daihom, Baher; Adhikari, Hitesh; Mishra, Sanjay; Helms, Richard; Almoazen, Hassan.

In: Drug Development and Industrial Pharmacy, Vol. 42, No. 10, 02.10.2016, p. 1579-1589.

Research output: Contribution to journalArticle

@article{4dc44f59e3fe4066bec2f41986852b31,
title = "Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics",
abstract = "Abstract: Purpose: The purpose of this study is to develop an oral suspension of clindamycin resin complex for the potential use in pediatrics. Methods: Several types of Ion exchange resins were screened for their binding efficiency with clindamycin. In order to develop a suspension formulation, several thickening agents, surfactants, sweeting, and flavoring agents were evaluated for their influence on the release of clindamycin from resinate. Rheological studies were also conducted to select the optimum amounts of the suspending agents. The release profiles of clindamycin in SGF and SIF were also evaluated from freshly prepared suspension and from suspension formulation after storage for 1 month at 25 °C and 40 °C. Clindamycin bitterness threshold was determined based on volunteers’ evaluation, and taste evaluation was conducted in 12 adult volunteers who evaluated the taste of the optimized suspension against clindamycin solution. Results: Among all resins tested, Amberlite IRP 69 showed the highest binding efficiency to clindamycin. Several excipients were selected into the suspension formulation based on no or minimum influence on the release of clindamycin from the resinate complex. Moreover, xanthan gum was selected as the optimal suspending agent for the suspension. Clindamycin release profiles in SGF or SIF showed 90{\%} release within 30 min from freshly prepared sample. Clindamycin exhibited good stability profiles at 25 °C and 40 °C over 1 month storage. The mean bitterness threshold of clindamycin was 12.5 μg/ml, and taste evaluation study in adults showed sustainable taste improvement for suspension over clindamycin solution. Conclusion: Clindamycin/resin complexation has shown to be an efficient method to mask the taste of clindamycin and was developed into a suspension formulation that can be used in pediatrics.",
author = "Alaadin Alayoubi and Baher Daihom and Hitesh Adhikari and Sanjay Mishra and Richard Helms and Hassan Almoazen",
year = "2016",
month = "10",
day = "2",
doi = "10.3109/03639045.2016.1160102",
language = "English (US)",
volume = "42",
pages = "1579--1589",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics

AU - Alayoubi, Alaadin

AU - Daihom, Baher

AU - Adhikari, Hitesh

AU - Mishra, Sanjay

AU - Helms, Richard

AU - Almoazen, Hassan

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Abstract: Purpose: The purpose of this study is to develop an oral suspension of clindamycin resin complex for the potential use in pediatrics. Methods: Several types of Ion exchange resins were screened for their binding efficiency with clindamycin. In order to develop a suspension formulation, several thickening agents, surfactants, sweeting, and flavoring agents were evaluated for their influence on the release of clindamycin from resinate. Rheological studies were also conducted to select the optimum amounts of the suspending agents. The release profiles of clindamycin in SGF and SIF were also evaluated from freshly prepared suspension and from suspension formulation after storage for 1 month at 25 °C and 40 °C. Clindamycin bitterness threshold was determined based on volunteers’ evaluation, and taste evaluation was conducted in 12 adult volunteers who evaluated the taste of the optimized suspension against clindamycin solution. Results: Among all resins tested, Amberlite IRP 69 showed the highest binding efficiency to clindamycin. Several excipients were selected into the suspension formulation based on no or minimum influence on the release of clindamycin from the resinate complex. Moreover, xanthan gum was selected as the optimal suspending agent for the suspension. Clindamycin release profiles in SGF or SIF showed 90% release within 30 min from freshly prepared sample. Clindamycin exhibited good stability profiles at 25 °C and 40 °C over 1 month storage. The mean bitterness threshold of clindamycin was 12.5 μg/ml, and taste evaluation study in adults showed sustainable taste improvement for suspension over clindamycin solution. Conclusion: Clindamycin/resin complexation has shown to be an efficient method to mask the taste of clindamycin and was developed into a suspension formulation that can be used in pediatrics.

AB - Abstract: Purpose: The purpose of this study is to develop an oral suspension of clindamycin resin complex for the potential use in pediatrics. Methods: Several types of Ion exchange resins were screened for their binding efficiency with clindamycin. In order to develop a suspension formulation, several thickening agents, surfactants, sweeting, and flavoring agents were evaluated for their influence on the release of clindamycin from resinate. Rheological studies were also conducted to select the optimum amounts of the suspending agents. The release profiles of clindamycin in SGF and SIF were also evaluated from freshly prepared suspension and from suspension formulation after storage for 1 month at 25 °C and 40 °C. Clindamycin bitterness threshold was determined based on volunteers’ evaluation, and taste evaluation was conducted in 12 adult volunteers who evaluated the taste of the optimized suspension against clindamycin solution. Results: Among all resins tested, Amberlite IRP 69 showed the highest binding efficiency to clindamycin. Several excipients were selected into the suspension formulation based on no or minimum influence on the release of clindamycin from the resinate complex. Moreover, xanthan gum was selected as the optimal suspending agent for the suspension. Clindamycin release profiles in SGF or SIF showed 90% release within 30 min from freshly prepared sample. Clindamycin exhibited good stability profiles at 25 °C and 40 °C over 1 month storage. The mean bitterness threshold of clindamycin was 12.5 μg/ml, and taste evaluation study in adults showed sustainable taste improvement for suspension over clindamycin solution. Conclusion: Clindamycin/resin complexation has shown to be an efficient method to mask the taste of clindamycin and was developed into a suspension formulation that can be used in pediatrics.

UR - http://www.scopus.com/inward/record.url?scp=84965047380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965047380&partnerID=8YFLogxK

U2 - 10.3109/03639045.2016.1160102

DO - 10.3109/03639045.2016.1160102

M3 - Article

VL - 42

SP - 1579

EP - 1589

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

IS - 10

ER -